<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03125135</url>
  </required_header>
  <id_info>
    <org_study_id>TR27761-TP16850A</org_study_id>
    <nct_id>NCT03125135</nct_id>
  </id_info>
  <brief_title>Accuracy of Noninvasive Pulse Oximeter Sensor (MightySat RX)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masimo Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masimo Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the level of oxygen within the blood will be reduced in a controlled manner by&#xD;
      reducing the concentration of oxygen the study volunteer breathes. The accuracy of a&#xD;
      noninvasive pulse oximeter sensor will be assessed by comparison to the oxygen saturation&#xD;
      measurements from a laboratory blood gas analyzer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 12, 2014</start_date>
  <completion_date type="Actual">December 17, 2014</completion_date>
  <primary_completion_date type="Actual">December 17, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of Sensor</measure>
    <time_frame>1-5 hours</time_frame>
    <description>Accuracy will be determined by comparing the noninvasive blood oxygen saturation measurement of the pulse oximeter to that obtained from a blood sample and calculating the arithmetic root mean square error (Arms) value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy of Sensor during motion</measure>
    <time_frame>1-5 hours</time_frame>
    <description>Accuracy will be determined by comparing the noninvasive blood oxygen saturation measurement of the pulse oximeter to that obtained from a blood sample during motion conditions and calculating the arithmetic root mean square error (Arms) value.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Subject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects are enrolled into the test group and all subjects receive the MightySat RX Pulse Oximeter Sensor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MightySat RX Pulse Oximeter Sensor</intervention_name>
    <description>Noninvasive pulse oximeter finger sensor.</description>
    <arm_group_label>Test Subject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Competent non-smoking adults&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must understand and consent to be in the study.&#xD;
&#xD;
          -  American Society of Anesthesiology Class 1 (Healthy subjects without any systemic&#xD;
             disease at all).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have any systemic disease at all.&#xD;
&#xD;
          -  Subjects who do not understand the study and the risks.&#xD;
&#xD;
          -  Smokers.&#xD;
&#xD;
          -  Subjects who are pregnant.&#xD;
&#xD;
          -  Subjects having either signs or history of peripheral ischemia.&#xD;
&#xD;
          -  Others deemed ineligible by the clinical staff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Masimo Corporation</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

